Acute Intermittent Porphyria Global Market Report 2025

Acute Intermittent Porphyria Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute intermittent porphyria market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description:

Where is the largest and fastest growing market for acute intermittent porphyria ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute intermittent porphyria market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:1) By Diagnosis: Urine Test; Blood Test; Serum Test; DNA Test; Other Diagnosis

2) By Treatment: Prophylactic Hematin Infusions; Gonadotropin-Releasing Hormone Analogues; Other Treatments

3) By End-Users: Hospitals And Clinics; Ambulatory Surgical Centers; Research Centers

Subsegments:

1) By Urine Test: Urine Porphobilinogen (PBG) Test; Urine Aminolevulinic Acid (ALA) Test; Urine Color Change Test

2) By Blood Test: Plasma Porphyrin Levels Test; Blood Aminolevulinic Acid (ALA) Test; Complete Blood Count (CBC) Test

3) By Serum Test: Serum Porphyrin Levels Test; Liver Function Test (LFT); Serum ALA and PBG Enzyme Test

4) By DNA Test: Genetic Mutation Testing; Gene Sequencing Test

5) By Other Diagnosis: Stool Test for Porphyrins; Imaging Tests (CT/MRI Scans for Complications); Enzyme Activity Assays.

Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.


1. Executive Summary
2. Acute Intermittent Porphyria Market Characteristics
3. Acute Intermittent Porphyria Market Trends And Strategies
4. Acute Intermittent Porphyria Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Acute Intermittent Porphyria Growth Analysis And Strategic Analysis Framework
5.1. Global Acute Intermittent Porphyria PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Acute Intermittent Porphyria Market Growth Rate Analysis
5.4. Global Acute Intermittent Porphyria Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Acute Intermittent Porphyria Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Acute Intermittent Porphyria Total Addressable Market (TAM)
6. Acute Intermittent Porphyria Market Segmentation
6.1. Global Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Urine Test
Blood Test
Serum Test
DNA Test
Other Diagnosis
6.2. Global Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prophylactic Hematin Infusions
Gonadotropin-Releasing Hormone Analogues
Other Treatments
6.3. Global Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals and Clinics
Ambulatory Surgical Centers
Research Centers
6.4. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Urine Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Urine Porphobilinogen (PBG) Test
Urine Aminolevulinic Acid (ALA) Test
Urine Color Change Test
6.5. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Blood Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plasma Porphyrin Levels Test
Blood Aminolevulinic Acid (ALA) Test
Complete Blood Count (CBC) Test
6.6. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Serum Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Serum Porphyrin Levels Test
Liver Function Test (LFT)
Serum ALA and PBG Enzyme Test
6.7. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of DNA Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Genetic Mutation Testing
Gene Sequencing Test
6.8. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Other Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stool Test for Porphyrins
Imaging Tests (CT/MRI Scans for Complications)
Enzyme Activity Assays
7. Acute Intermittent Porphyria Market Regional And Country Analysis
7.1. Global Acute Intermittent Porphyria Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Acute Intermittent Porphyria Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Acute Intermittent Porphyria Market
8.1. Asia-Pacific Acute Intermittent Porphyria Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Acute Intermittent Porphyria Market
9.1. China Acute Intermittent Porphyria Market Overview
9.2. China Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Acute Intermittent Porphyria Market
10.1. India Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Acute Intermittent Porphyria Market
11.1. Japan Acute Intermittent Porphyria Market Overview
11.2. Japan Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Acute Intermittent Porphyria Market
12.1. Australia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Acute Intermittent Porphyria Market
13.1. Indonesia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Acute Intermittent Porphyria Market
14.1. South Korea Acute Intermittent Porphyria Market Overview
14.2. South Korea Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Acute Intermittent Porphyria Market
15.1. Western Europe Acute Intermittent Porphyria Market Overview
15.2. Western Europe Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Acute Intermittent Porphyria Market
16.1. UK Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Acute Intermittent Porphyria Market
17.1. Germany Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Acute Intermittent Porphyria Market
18.1. France Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Acute Intermittent Porphyria Market
19.1. Italy Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Acute Intermittent Porphyria Market
20.1. Spain Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Acute Intermittent Porphyria Market
21.1. Eastern Europe Acute Intermittent Porphyria Market Overview
21.2. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Acute Intermittent Porphyria Market
22.1. Russia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Acute Intermittent Porphyria Market
23.1. North America Acute Intermittent Porphyria Market Overview
23.2. North America Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Acute Intermittent Porphyria Market
24.1. USA Acute Intermittent Porphyria Market Overview
24.2. USA Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Acute Intermittent Porphyria Market
25.1. Canada Acute Intermittent Porphyria Market Overview
25.2. Canada Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Acute Intermittent Porphyria Market
26.1. South America Acute Intermittent Porphyria Market Overview
26.2. South America Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Acute Intermittent Porphyria Market
27.1. Brazil Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Acute Intermittent Porphyria Market
28.1. Middle East Acute Intermittent Porphyria Market Overview
28.2. Middle East Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Acute Intermittent Porphyria Market
29.1. Africa Acute Intermittent Porphyria Market Overview
29.2. Africa Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Acute Intermittent Porphyria Market Competitive Landscape And Company Profiles
30.1. Acute Intermittent Porphyria Market Competitive Landscape
30.2. Acute Intermittent Porphyria Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Acute Intermittent Porphyria Market Other Major And Innovative Companies
31.1. Sanofi SA
31.2. AstraZeneca Plc
31.3. Novartis AG
31.4. GlaxoSmithKline Plc
31.5. Takeda Pharmaceutical Company Limited
31.6. Eli Lilly and Company
31.7. Gilead Sciences Inc.
31.8. Amgen Inc.
31.9. Novo Nordisk A/S
31.10. Regeneron Pharmaceuticals Inc.
31.11. Daiichi Sankyo Company Limited
31.12. Vertex Pharmaceuticals Inc.
31.13. Eisai Co. Ltd.
31.14. Octapharma AG
31.15. BioMarin Pharmaceutical Inc.
32. Global Acute Intermittent Porphyria Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Acute Intermittent Porphyria Market
34. Recent Developments In The Acute Intermittent Porphyria Market
35. Acute Intermittent Porphyria Market High Potential Countries, Segments and Strategies
35.1 Acute Intermittent Porphyria Market In 2029 - Countries Offering Most New Opportunities
35.2 Acute Intermittent Porphyria Market In 2029 - Segments Offering Most New Opportunities
35.3 Acute Intermittent Porphyria Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings